From July 27th to 29th, the 2023 Shenzhen International Biomedical Industry Innovation and Development Conference was successfully held at the Yanzihu International Convention and Exhibition Center in Pingshan, Shenzhen. The theme of the conference was "Cross-border Integration, Deep into the Future," and it consisted of one main forum and nine parallel theme forums. In order to further promote the convergence of core resources in the biomedical industry, six major platform projects for bio-industry new infrastructure, including Anling Biomedical (Shenzhen) Co., Ltd. (referred to as "Anling Shenzhen"), a wholly-owned subsidiary of ZSHK, were formally published at the conference. Jin Yi, the general manager of Anling Shenzhen, attended and participated in the opening ceremony.

During the Innovation in Pharmaceutical Development theme forum, various enterprises presented their latest progress in research and development and exploration in their respective fields, in response to problems such as severe industry homogeneity and weak clinical translation capabilities. Jin Yi, the general manager of Anling Shenzhen, gave a keynote presentation on the "Design and Focus of Non-clinical Research in New Drug Development."

Through various forms of cross-border integration and communication, this conference will accelerate the development of the Pingshan and even the Shenzhen biomedical industry, forming an international, high-end, and specialized first-class medical innovation ecosystem. Anling Shenzhen had booth A11 at the event, attracting widespread attention and praise from industry clients, high-end talents, and media friends! They also welcome more clients to further understand and engage in business cooperation.